Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Cancer Research|June 17, 2010
PIK3CA mutations in in situ and invasive breast carcinomasAlexander Miron, Maria Varadi, Daniel Carrasco, et al.
Nature Communications|April 7, 2020
Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineagesJennifer M Rosenbluth, Ron C J Schackmann, G Kenneth Gray, et al.
The Oncologist|March 25, 2016
Benign and Malignant Breast Disease at Rwanda's First Public Cancer Referral CenterLydia E Pace, Jean-Marie V Dusengimana, Vedaste Hategekimana, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 14, 2021
Exploring the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgeryRobert Knoerl, Anita Giobbie-Hurder, Timothy S Sannes, et al.
Cancer Cell|January 1, 2021
Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast CancerArchis Bagati, Sushil Kumar, Peng Jiang, et al.
Clinical Breast Cancer|March 2, 2020
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast CancerRomualdo Barroso-Sousa, Ian E Krop, Lorenzo Trippa, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progressionJun Nishida, Simona Cristea, Sudheshna Bodapati, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesTam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
Pageof 10